Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cystic Fibrosis in Children Clear all

Conditions: Cystic Fibrosis
Interventions: Linezolid; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cystic Fibrosis (CF), Pancreatic Insufficiency, Pancreas Disease, Exocrine Pancreatic Insufficiency, Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis, CFTR Gene Mutation
Interventions: Discontinuation of Pancreatic Enzyme Replacement Therapy; Drug
Lead sponsor: Indiana University; Other
Eligibility: 0 Years to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: GERD in Children, Cystic Fibrosis in Children
Interventions: Discontinuation of GERD therapy; Other
Lead sponsor: Duke University; Other
Eligibility: 2 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1996
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cystic Fibrosis-related Diabetes, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis in Children
Interventions: Sensor Augmented Pump Therapy, Standard of Care with CGM; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 2 Months to 5 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Lym-X-Sorb powder, Placebo powder; Dietary Supplement
Lead sponsor: Avanti Polar Lipids, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Ultrase® MT12; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 15
States / cities: Aurora, Colorado • Ann Arbor, Michigan • Grand Rapids, Michigan + 11 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: Ultrase® MT20; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Hershey, Pennsylvania

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 7 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Pseudomonas Aeruginosa, Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Zafer Soultan; Other
Eligibility: 5 Years to 19 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Cystic Fibrosis
Interventions: Ceftaroline; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cystic Fibrosis
Interventions: Hyperpolarized Xenon; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 12 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cystic Fibrosis (CF)
Interventions: Not listed
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Months to 11 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Hollywood, Florida + 10 more

Conditions: Cystic Fibrosis in Children, Cystic Fibrosis, Chronic Rhinosinusitis (Diagnosis), Olfactory Disorder, Olfactory Impairment
Interventions: Ivacaftor or elexacaftor/tezacaftor/ivacaftor; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 2 Years to 8 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Aurora, Colorado • Iowa City, Iowa • Kansas City, Kansas + 3 more

Conditions: Cystic Fibrosis
Interventions: Essential amino acid intake + Leucine vs total AA supplement; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 10 Years to 21 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Cystic Fibrosis, Cystic Fibrosis in Children
Interventions: Not listed
Lead sponsor: Nicole Hamblett; Other
Eligibility: 6 Years to 11 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 20
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 17 more

Conditions: Cystic Fibrosis
Interventions: Oral Glucose tolerance test, Whole body protein turnover, IV glucose tolerance test, Indirect Calorimetry, Dual Energy X-ray Absorptiometry (DEXA), Growth Hormone Stimulation Test; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 7 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cystic Fibrosis, Pancreatic Exocrine Insufficiency
Interventions: Pancrelipase Delayed Release; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 1 Month to 6 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Boise, Idaho • Louisville, Kentucky • Boston, Massachusetts + 8 more

Conditions: Cystic Fibrosis in Children
Interventions: 19F MRI; Combination Product
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 6 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Oral glucose tolerance test, Continuous glucose monitoring, Dexa scan; Diagnostic Test
Lead sponsor: Katie Larson Ode; Other
Eligibility: 6 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Aurora, Colorado • Iowa City, Iowa • Minneapolis, Minnesota + 1 more

Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Interventions: PANCRECARB® (pancrelipase), Placebo; Drug
Lead sponsor: Digestive Care, Inc.; Industry
Eligibility: 7 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cystic Fibrosis in Children
Interventions: Jamboxx Respiratory Therapy Device, Autogenic Draining Training; Device · Other
Lead sponsor: My Music Machines Inc.; Industry
Eligibility: 5 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Albany, New York

Conditions: Cystic Fibrosis
Interventions: Lung T1 MRI; Diagnostic Test
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 5 Years to 11 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Cleveland, Ohio

Search by objective public record fields.

Pharmacokinetics of Linezolid in Children With Cystic Fibrosis

Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

GERD in Children With Cystic Fibrosis

Study of Total Energy Expenditure in Infants and Children With Moderate to Severe Cystic Fibrosis

Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management

Controlled Ventilation CT in CF Infants

Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Assessment of Fat Free Mass Index and Its Impact on Health in Children With Cystic Fibrosis

The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis

Pharmacokinetic and Pharmacodynamic Analysis of Ceftaroline in Children and Adolescents With Cystic Fibrosis

Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI

TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

Sinus Disease in Young Children With Cystic Fibrosis

Leucine-enriched Essential Amino Acid Intake to Optimize Protein Anabolism in Children With Cystic Fibrosis

The PROMISE Pediatric Study 6 to 11 Years Old

Metabolic Abnormalities in Hispanic Children With Cystic Fibrosis

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis

Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis

The Effectiveness of the Jamboxx Respiratory Therapy Device: Study 2

Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients